With deep ties to Baylor and fresh support from Polaris, Singapore's Tessa raises $126M for pivotal CAR study
Tessa Therapeutics in Singapore has been through multiple raises over the last decade for its cell therapy R&D work. But with US-based VC Polaris stepping in to lead the new $126 million round as it sits on the threshold of a pivotal expedition in the clinic focused on the US and Europe, they’re calling this new one today a Series A.
That fresh raise comes on top of the more than $200 million already garnered for its work, interim CEO John Ng tells me. Temasek, the $283 billion sovereign wealth fund in Singapore that’s played a major role in building the country’s tech industry, has been a key player here. EDBI, Heliconia Capital and Heritas Capital also figure in as existing investors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.